CO5130026A1 - METODO PARA TRATAR DIABETES EMPLEANDO UN INHIBIDOR ap2 Y COMBINACION - Google Patents

METODO PARA TRATAR DIABETES EMPLEANDO UN INHIBIDOR ap2 Y COMBINACION

Info

Publication number
CO5130026A1
CO5130026A1 CO99058376A CO99058376A CO5130026A1 CO 5130026 A1 CO5130026 A1 CO 5130026A1 CO 99058376 A CO99058376 A CO 99058376A CO 99058376 A CO99058376 A CO 99058376A CO 5130026 A1 CO5130026 A1 CO 5130026A1
Authority
CO
Colombia
Prior art keywords
inhibitor
combination
jpeg
fatty acids
treat diabetes
Prior art date
Application number
CO99058376A
Other languages
English (en)
Inventor
Jeffrey A Robl
A Parker Rex
Scott A Biller
Haris Jamil
Bruce L Jacobson
Kodukula Krishna
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5130026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO5130026A1 publication Critical patent/CO5130026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)

Abstract

Un método para tratar la diabetes, resistencia a la insulina, obesidad, hiperglicemia, hiperinsulinemia, o cantidades elevadas de ácidos grasos, glicerol, o hipertrigliceridemia, caracterizado porque comprende administrar a una especie de mamífero en necesidad de tratamiento una cantidad terapéuticamente efectiva de un inhibidor aP2.El método definido en la reivindicación 1, caracterizado porque el inhibidor aP2 se une a la proteína aP2 e inhibe su función y/o su capacidad de unir ácidos grasos libres.<EMI FILE="99058376_1" ID="1" IMF=JPEG ><EMI FILE="99058376_2" ID="2" IMF=JPEG >
CO99058376A 1998-09-17 1999-09-15 METODO PARA TRATAR DIABETES EMPLEANDO UN INHIBIDOR ap2 Y COMBINACION CO5130026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10067798P 1998-09-17 1998-09-17

Publications (1)

Publication Number Publication Date
CO5130026A1 true CO5130026A1 (es) 2002-02-27

Family

ID=22280975

Family Applications (2)

Application Number Title Priority Date Filing Date
CO99058374A CO5130025A1 (es) 1998-09-17 1999-09-15 METODO PARA TRATAR ATEROESCLEROSIS EMPLEANDO UN INHIBIDOR DE ap2 Y COMBINACION
CO99058376A CO5130026A1 (es) 1998-09-17 1999-09-15 METODO PARA TRATAR DIABETES EMPLEANDO UN INHIBIDOR ap2 Y COMBINACION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CO99058374A CO5130025A1 (es) 1998-09-17 1999-09-15 METODO PARA TRATAR ATEROESCLEROSIS EMPLEANDO UN INHIBIDOR DE ap2 Y COMBINACION

Country Status (30)

Country Link
US (1) US20020035064A1 (es)
EP (2) EP1113801A4 (es)
JP (2) JP2002524518A (es)
KR (2) KR20010075150A (es)
CN (2) CN1319012A (es)
AT (1) ATE406898T1 (es)
AU (2) AU754488B2 (es)
BG (2) BG105432A (es)
BR (2) BR9913833A (es)
CA (2) CA2344309A1 (es)
CO (2) CO5130025A1 (es)
CZ (2) CZ2001965A3 (es)
DE (1) DE69939481D1 (es)
EE (2) EE200100155A (es)
ES (1) ES2311306T3 (es)
GE (2) GEP20033045B (es)
HU (2) HUP0104240A2 (es)
ID (2) ID28450A (es)
IL (2) IL141785A0 (es)
LT (2) LT4870B (es)
LV (2) LV12687B (es)
NO (2) NO20011351L (es)
NZ (2) NZ510209A (es)
PE (2) PE20001047A1 (es)
PL (2) PL346660A1 (es)
SK (1) SK3202001A3 (es)
TR (2) TR200100774T2 (es)
UY (2) UY25714A1 (es)
WO (2) WO2000015229A1 (es)
ZA (2) ZA200207433B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047423B1 (en) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Novel apoptosis inhibitors
ATE419346T1 (de) * 1999-02-12 2009-01-15 Harvard College Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren
AU2005201289B2 (en) * 1999-02-12 2008-04-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
WO2001054694A1 (en) 2000-01-28 2001-08-02 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
WO2002040448A1 (en) * 2000-11-20 2002-05-23 Bristol-Myers Squibb Company Pyridone derivatives as ap2 inhibitors
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
EP1414461A4 (en) 2001-07-13 2005-10-26 Bristol Myers Squibb Co PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD
AU2002322585A1 (en) * 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
EP1590336B1 (en) 2003-01-27 2010-12-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US20070043512A1 (en) * 2003-03-26 2007-02-22 Michael Rolph Therapeutic and prophylactic compositions and uses therefor
WO2004096977A2 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
CA2558766A1 (en) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
AU2005252183B2 (en) 2004-06-04 2008-07-17 Merck Sharp & Dohme Corp. Pyrazole derivatives, compositions containing such compounds and methods of use
SG164378A1 (en) 2005-02-17 2010-09-29 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
JP2009502923A (ja) 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド 置換ピラゾールを合成するための方法
EP1951224A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
WO2007143164A1 (en) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
JP2010513534A (ja) * 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ， インコーポレイテッド Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
JP2012508692A (ja) * 2008-11-12 2012-04-12 シェーリング コーポレイション 脂肪酸結合タンパク質（ｆａｂｐ）の阻害薬
DK2403605T3 (en) 2009-03-05 2015-07-20 Harvard College Compositions comprising an aP2-specific antibody or fragment thereof for use in the treatment of diabetes, glucose intolerance or insulin resistance induced by obesity
JP6223376B2 (ja) * 2014-03-24 2017-11-01 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6514282B2 (ja) * 2014-03-24 2019-05-15 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
TW201702271A (zh) 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 治療代謝病症之抗－ａｐ２抗體及抗原結合劑
CN109642908B (zh) * 2016-06-27 2022-08-16 哈佛学院院长及董事 可用于治疗代谢病症的化合物
AU2018279950A1 (en) 2017-06-09 2020-01-30 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2129012A1 (de) 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
FR2156486A1 (en) 1971-10-22 1973-06-01 Roussel Uclaf Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (es) 1974-06-07 1981-03-18
GB1507032A (en) 1974-08-06 1978-04-12 Serono Lab 2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
GB2205837B (en) 1987-05-22 1991-11-20 Squibb & Sons Inc Phosphorus-containing hmg-coa reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5218124A (en) * 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
PT95690A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr) 1990-06-14 1994-05-06 Bellon Laboratoires Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) * 1990-09-11 1990-10-24 Smith Kline French Lab Compounds
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5254576A (en) * 1992-04-03 1993-10-19 Bristol-Myers Squibb Company Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de) 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
RU2176640C2 (ru) * 1993-12-20 2001-12-10 Фудзисава Фармасьютикал Ко., Лтд. Гетероциклические соединения или их фармацевтически приемлемая соль, промежуточные соединения
US5599770A (en) 1994-07-15 1997-02-04 Kureha Kagaku Kogyo Kabushiki Kaisha Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk) 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en) 1996-01-05 1996-03-06 Foster Wheeler Petrol Dev Ltd Spacing bouy for flexible risers
AUPO134596A0 (en) 1996-08-01 1996-08-22 Jal Pastoral Co. Pty Ltd Demountable article carrier for motor vehicles
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
BR9913831A (pt) 2001-05-29
HUP0104240A2 (hu) 2002-03-28
EE200100154A (et) 2002-12-16
CO5130025A1 (es) 2002-02-27
LT4870B (lt) 2001-12-27
BG105432A (en) 2001-12-29
GEP20033045B (en) 2003-08-25
NO20011352D0 (no) 2001-03-16
US20020035064A1 (en) 2002-03-21
LV12687A (en) 2001-07-20
AU754488B2 (en) 2002-11-14
SK3202001A3 (en) 2002-04-04
NZ510209A (en) 2003-07-25
LT2001023A (en) 2001-08-27
BG105431A (en) 2001-12-29
LV12686A (en) 2001-07-20
TR200100773T2 (tr) 2001-07-23
EE04356B1 (et) 2004-10-15
JP2002524517A (ja) 2002-08-06
NZ510207A (en) 2003-08-29
PE20001056A1 (es) 2000-12-24
BR9913833A (pt) 2001-05-29
WO2000015229A1 (en) 2000-03-23
EP1121129A1 (en) 2001-08-08
EE200100155A (et) 2002-08-15
AU755563B2 (en) 2002-12-12
ZA200207433B (en) 2003-10-27
PE20001047A1 (es) 2000-12-24
ID27833A (id) 2001-04-26
LV12687B (lv) 2001-10-20
CN1317970A (zh) 2001-10-17
CA2344300A1 (en) 2000-03-23
ES2311306T3 (es) 2009-02-01
CZ2001964A3 (cs) 2002-01-16
EP1113801A1 (en) 2001-07-11
EP1113801A4 (en) 2002-10-02
HUP0104108A2 (hu) 2002-03-28
CN1319012A (zh) 2001-10-24
UY25714A1 (es) 2001-08-27
UY25713A1 (es) 2001-08-27
LT2001022A (en) 2001-08-27
LT4871B (lt) 2001-12-27
LV12686B (lv) 2001-10-20
NO20011351D0 (no) 2001-03-16
AU6387799A (en) 2000-04-03
EP1121129B1 (en) 2008-09-03
PL346660A1 (en) 2002-02-25
IL141786A0 (en) 2002-03-10
ZA200207430B (en) 2003-09-16
CA2344309A1 (en) 2000-03-23
AU6143799A (en) 2000-04-03
ID28450A (id) 2001-05-24
GEP20033044B (en) 2003-08-25
IL141785A0 (en) 2002-03-10
KR20010079842A (ko) 2001-08-22
JP2002524518A (ja) 2002-08-06
TR200100774T2 (tr) 2001-12-21
EP1121129A4 (en) 2002-10-16
DE69939481D1 (de) 2008-10-16
WO2000015230A1 (en) 2000-03-23
KR20010075150A (ko) 2001-08-09
NO20011352L (no) 2001-05-11
CZ2001965A3 (cs) 2002-02-13
PL346661A1 (en) 2002-02-25
ATE406898T1 (de) 2008-09-15
NO20011351L (no) 2001-05-11

Similar Documents

Publication Publication Date Title
CO5130026A1 (es) METODO PARA TRATAR DIABETES EMPLEANDO UN INHIBIDOR ap2 Y COMBINACION
CO5280216A1 (es) Tratamiento de la enfermendad neurodegenerativa
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
BR0100106A (pt) Tratamento para a obesidade e métodos para a identificação de compostos úteis para o tratamento da obesidade
EA200101089A1 (ru) Новый способ лечения
BR0113400A (pt) Método para seleção de peptìdeo
DE69115247D1 (de) Behandlung von fettleibigkeit mit einem alpha-2-adrenergen-agonisten und einem wachstumshormon freigebenden peptid.
EA200601059A1 (ru) Сложные моноэфиры пробукола для лечения сердечно-сосудистых и воспалительных заболеваний
DE60116256D1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
CO5190684A1 (es) Uso de antagonistas del factor de liberador de corticotropi- na (corticoliberina o crf) y composiciones relacionadas
BE2012C005I2 (es)
EA200000994A1 (ru) Применение кабэрголина при лечении синдрома усталых ног
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
DK0942740T3 (da) Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
BRPI0415195A (pt) anticorpos completamente humanos contra 4-1bb humana (cd137)
BRPI0413489B8 (pt) molécula de anticorpo anti-cd20 fusionada a il-2 e composição farmacêutica compreendendo a mesma
EA200100573A1 (ru) Применение ингибитора циклооксигеназы-2, ингибитора матричной металлопротеиназы, противоопухолевого лекарственного средства и факультативно облучения в качестве комбинированного способа лечения неоплазии
ATE339450T1 (de) Verfahren zur behandlung von entzündungen
CY1107087T1 (el) Μιμητικα θρομβοποιητινης
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
DE3774279D1 (de) Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe.
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
Mirone et al. Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica